Trial Profile
A 12 Month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Corticosteroids; Tacrolimus
- Indications Liver transplant rejection
- Focus Therapeutic Use
- Acronyms HEPHAISTOS
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Sep 2021 Primary endpoint (Estimated Glomerular Filtration Rate (GFR)) has been met, as per results published in the Liver Transplantation.
- 15 Sep 2021 Results assessing effects of early initiation of Everolimus-facilitated reduced tacrolimus exposure (EVR+rTAC) in de novo liver transplant recipients (LTR), published in the Liver Transplantation.
- 03 Jun 2020 Results assessing discontinuation rates in multicentre trials presented at the 2020 American Transplant Congress